Evolving Approaches to ALL Treatment: CAR T-cell Therapy

Pere Barba, MD, PhD, discusses the safety of obecabtagene autoleucel in patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

Daniel DeAngelo MD, PhD, discusses the data seen with obecabtagene autoleucel as a novel treatment in the CAR T-cell arena, emphasizes unmet needs in B-cell acute lymphoblastic leukemia, and highlights important next steps in the study of obe-cel.

Daniel J. DeAngelo, MD, PhD, discusses rates of cytokine release syndrome with obecabtagene autoleucel in acute lymphoblastic leukemia.

Efforts are underway to evaluate novel, durable treatment options for adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia in the phase 1b/2 FELIX trial evaluating obecabtagene autoleucel, a novel, second-generation CAR T-cell therapy.

Jae Park, MD, discusses dosing strategies utilized in the phase 1/2 FELIX trial in relapsed/refractory acute lymphoblastic leukemia.

Claire Roddie, MD, discusses the potential utilization of obecabtagene autoleucel in relapsed/refractory acute lymphoblastic leukemia.

Claire Roddie, MD, PhD, discusses how the phase 1/2 FELIX trial could impact the treatment landscape for acute lymphoblastic leukemia, how CAR T-cell therapies have evolved, and what challenges remain in making these treatments more accessible for patients.

The safety and efficacy of the CD19-targeted CAR T-cell therapy obecabtagene autoleucel in the treatment of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia as part of the phase 1/2 FELIX trial.